Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical firm, will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto from April 25-26, 2023. The company's presentation is scheduled for April 25, 2023, at 11:00 am Eastern Time (8:00 am Pacific Time). Investors can register for a live webcast of the event here. Ian Mortimer, the President and CEO, will be the presenter. A replay of the webcast will be available on the company's website post-event. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The company will participate in a fireside chat on April 20, 2023, at 2:15 PM ET (11:15 AM PT). Company executives Ian Mortimer (President and CEO) and Sherry Aulin (CFO) will present. Investors can access a live webcast of the presentation on Xenon's website, with a replay available post-event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly in epilepsy, with a commitment to addressing unmet medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company focused on neurology, will present at the virtual Stifel 2023 CNS Days on March 28-29, 2023. The presentation will feature Ian Mortimer, President and CEO, and Sherry Aulin, CFO, on March 28 at 1:00 PM Eastern Time (10:00 AM Pacific Time). A live webcast will be available and can be pre-registered for via a provided link. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly epilepsy. For further information, visit www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) has advanced its XEN1101 Phase 3 epilepsy program, with ongoing trials including X-TOLE2, X-TOLE3, and X-ACKT. The company expects topline results from the XEN1101 Phase 2 X-NOVA study in major depressive disorder by Q3 2023. Financially, Xenon reported a net loss of $125.4 million for 2022, an increase from $78.9 million in 2021, due to higher R&D and G&A expenses. Cash reserves as of December 31, 2022, were $720.8 million, enough to fund operations until 2026. The company aims to address unmet needs in epilepsy and mental health disorders with its innovative therapies.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its fourth quarter and full year 2022 financial results on March 1, 2023, after U.S. markets close. The company specializes in developing neurology-focused biopharmaceuticals, particularly for epilepsy. A conference call will be held at 4:30 PM ET the same day, with dial-in numbers provided for both domestic and international callers. Additionally, a live audio webcast will be available in the Investors section of their website, offering a replay option post-event.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its participation in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. A key event will be a fireside chat on February 15, 2023, at 3:00 PM ET, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO.
A live webcast will be available on their website, with a replay posted after the event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found at www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) announced advancements in its XEN1101 Phase 3 epilepsy program, now active in both focal onset seizures and primary generalized tonic clonic seizures. The company is financially robust, expecting to fund its operations until 2026. The X-TOLE2 study for focal seizures is underway, with the newly initiated X-ACKT trial targeting generalized seizures. Data from the X-NOVA study on major depressive disorder is anticipated in Q3 2023, alongside collaboration updates with Neurocrine Biosciences.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 9, 2023, at 7:30 am PT (10:30 am ET), led by President and CEO Ian Mortimer. Investors can access a live webcast of the presentation on the company’s website, with a replay available afterward. Xenon focuses on developing innovative treatments for neurological disorders, particularly epilepsy, aiming to address significant unmet medical needs.
Xenon Pharmaceuticals (Nasdaq:XENE) presented positive interim data from the Phase 2b open-label extension of its XEN1101 clinical trial for focal onset seizures at the American Epilepsy Society (AES 2022). Key findings show sustained seizure reduction of 80%-90%, with 17.5% and 10.5% of patients achieving 6- and 12-month seizure freedom, respectively. XEN1101 was well-tolerated, and the ongoing Phase 3 program aims to confirm these results. The trial included a difficult-to-treat patient population, suggesting robust efficacy that may enhance XEN1101's market potential.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in one-on-one investor meetings and a fireside chat at the Bank of America Securities Biotech SMID Cap Conference 2022. The event will be held virtually on December 7-8, 2022. Ian Mortimer, President and CEO, along with Sherry Aulin, CFO, will present on December 7 at 1:10 pm Eastern Time. A webcast of the presentation will be accessible on the company’s website for later viewing. Xenon Pharmaceuticals focuses on developing innovative therapies for neurological disorders, particularly epilepsy.